In a renewed case of controversy, the Supreme Court of the United States has chosen not to reevaluate the subject matter eligibility of diagnostic claims, following the filing of a writ of certiorari by CareDx Inc. and the Board of Trustees of Leland Stanford Junior University, collectively referred to as CareDx. This is not the first time that the court has declined to evaluate this particular legal territory, further reinforcing its stance.
The petition filed by CareDx sought to have the Court address a specific question, details of which have been withheld at this stage. In response to the petition, the Supreme Court requested responses from Natera Inc. and Eurofins Viracor Inc., the respondents in this case. Based on the court’s actions, there seemed to be, at least to a small degree, interest in addressing the eligibility of diagnostic claims.
The purported interest in the case by the Supreme Court has drawn the attention of legal and corporate entities, as this could potentially influence ongoing and future case laws and corporate actions grounded in the eligibility of diagnostic claims.
Subject matter eligibility of diagnostic claims have long been a complex and somewhat controversial territory in legal circles. With this recent development, the uncertainties and complexities of these cases remain, as the Supreme Court continues to decline to issue a definitive ruling on the matter. The implcation of this for the broader corporate landscape remains unclear, as businesses continue to grapple with the uncertainties inherent in such claims.
For further details on the Supreme Court’s decision and its potential implications, you can consult the full report provided by BakerHostetler on JDSupra.